OncoMatch/Clinical Trials/NCT05717166
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
Is NCT05717166 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Chemotherapy and Hormone therapy for metastatic tumor.
Treatment: Chemotherapy · Hormone therapy · Immunotherapy · Targeted Systemic Therapy — This study is a phase III multi-institutional randomized trial. Patients will be randomized in a 1:2 ratio between current standard of care treatment (Arm 1) vs. standard of care treatment + SABR (Arm 2) to sites of known disease. Patients will be stratified by two of the strongest prognostic factors, based on a large multi-institutional analysis3: histology (Group 1: hormone-sensitive prostate cancer, breast, or renal; Group 2: all others), and number of metastases (Group 1: 1-3; Group 2: 4-10).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Metastatic disease required
Performance status
KARNOFSKY 61–100
Karnofsky performance status > 60
Lab requirements
Liver function
For patients with liver metastases, moderate/severe liver dysfunction (Child Pugh B or C) excluded.
For patients with liver metastases, moderate/severe liver dysfunction (Child Pugh B or C); please see the Child-Pugh score calculator.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05717166 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify